Pharmacogenetics in palliative care

Forensic Science International

Volumn 203, Issue 1-3, 2010, Pages 63-70

  Kleine Brueggeney, Maren ^a   Musshoff, Frank ^b   Stuber, Frank ^a   Stamer, Ulrike M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Analgesia; Cytochrome P450 (CYP); Opioids; Pain; Polymorphism; Tamoxifen

Indexed keywords

CATECHOL METHYLTRANSFERASE; CODEINE; CYTOCHROME P450 2D6; DIHYDROCODEINE; HYDROCODONE; METHADONE; MORPHINE; MU OPIATE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; NARCOTIC ANALGESIC AGENT; ONDANSETRON; OXYCODONE; OXYMORPHONE; PAROXETINE; REBOXETINE; RIFAMPICIN; SEROTONIN 3 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; TROPISETRON;

AGE; ANALGESIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PAIN; CHEMOTHERAPY INDUCED EMESIS; CHRONIC PAIN; CLINICAL TRIAL; COMORBIDITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INHIBITION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; ENZYME ACTIVITY; GASTROINTESTINAL TOXICITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MUTATIONAL ANALYSIS; NAUSEA AND VOMITING; NEUROPATHIC PAIN; PAIN; PALLIATIVE THERAPY; PATIENT ATTITUDE; PHARMACODYNAMICS; PHARMACOGENETICS; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RESPIRATION DEPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT;

EID: 78649326284     PISSN: 03790738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.forsciint.2010.07.003     Document Type: Article

References (107)

1. Skorpen F., Laugsand E.A., Klepstad P., Kaasa S. Variable response to opioid treatment: any genetic predictors within sight?. Palliat. Med. 2008, 22:310-327.
2. Lotsch J., Geisslinger G., Tegeder I. Genetic modulation of the pharmacological treatment of pain. Pharmacol. Ther. 2009, 124:168-184.
3. Rollason V., Samer C., Piguet V., Dayer P., Desmeules J. Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics 2008, 9:905-933.
4. Smith H.S. Variations in opioid responsiveness. Pain Phys. 2008, 11:237-248.
5. Ingelman-Sundberg M., Sim S.C., Gomez A., Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 2007, 116:496-526.
6. Eichelbaum M., Ingelman-Sundberg M., Evans W.E. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 2006, 57:119-137.
7. Wang B., Yang L.P., Zhang X.Z., Huang S.Q., Bartlam M., Zhou S.F. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab. Rev. 2009, 41:573-643.
8. D.A. Flockhart, Drug Interactions: Cytochrome P450 Drug Interaction Table, Indiana University School of Medicine, 2007. (retrieved November 2009). http://medicine.iupui.edu/clinpharm/ddis/table.asp.
9. Daly A.K., Brockmoller J., Broly F., Eichelbaum M., Evans W.E., Gonzalez F.J., Huang J.D., Idle J.R., Ingelman-Sundberg M., Ishizaki T., Jacqz-Aigrain E., Meyer U.A., Nebert D.W., Steen V.M., Wolf C.R., Zanger U.M. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996, 6:193-201.
10. The CYP Allele Nomenclature Committee. (retrieved November 2009). http://www.imm.ki.se/CYPalleles/.
11. Zhou S.F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin. Pharmacokinet. 2009, 48:689-723.
12. NCBI SNP database. (retrieved November 2009). http://www.ncbi.nlm.nih.gov/SNP.
13. Maddocks I., Somogyi A., Abbott F., Hayball P., Parker D. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J. Pain Symptom Manage. 1996, 12:182-189.
14. Gasche Y., Daali Y., Fathi M., Chiappe A., Cottini S., Dayer P., Desmeules J. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. 2004, 351:2827-2831.
15. Susce M.T., Murray-Carmichael E., de Leon J. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:1356-1358.
16. Koren G., Cairns J., Chitayat D., Gaedigk A., Leeder S.J. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006, 368:704.
17. Zhou S.F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin. Pharmacokinet. 2009, 48:761-804.
18. Williams D.G., Hatch D.J., Howard R.F. Codeine phosphate in paediatric medicine. Br. J. Anaesth. 2001, 86:413-421.
19. Poulsen L., Brosen K., Arendt-Nielsen L., Gram L.F., Elbaek K., Sindrup S.H. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur. J. Clin. Pharmacol. 1996, 51:289-295.
20. Persson K., Sjostrom S., Sigurdardottir I., Molnar V., Hammarlund-Udenaes M., Rane A. Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan. Br. J. Clin. Pharmacol. 1995, 39:182-186.
21. Williams D.G., Patel A., Howard R.F. Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br. J. Anaesth. 2002, 89:839-845.
22. Kirchheiner J., Schmidt H., Tzvetkov M., Keulen J.T., Lotsch J., Roots I., Brockmoller J. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007, 7:257-265.
23. Thorn C.F., Klein T.E., Altman R.B. Codeine and morphine pathway. Pharmacogenet. Genomics 2009, 19:556-558.
24. Stamer U.M., Zhang L., Stuber F. Personalized Therapy in Pain Management: Where do we stand?. Pharmacogenomics 2010, 11:843-864.
25. Otton S.V., Schadel M., Cheung S.W., Kaplan H.L., Busto U.E., Sellers E.M. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin. Pharmacol. Ther. 1993, 54:463-472.
26. Fromm M.F., Hofmann U., Griese E.U., Mikus G. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. Clin. Pharmacol. Ther. 1995, 58:374-382.
27. Wilder-Smith C.H., Hufschmid E., Thormann W. The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers. Br. J. Clin. Pharmacol. 1998, 45:575-581.
28. Hutchinson M.R., Menelaou A., Foster D.J., Coller J.K., Somogyi A.A. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br. J. Clin. Pharmacol. 2004, 57:287-297.
29. Scott L.J., Perry C.M. Tramadol: a review of its use in perioperative pain. Drugs 2000, 60:139-176.
30. Lai J., Ma S.W., Porreca F., Raffa R.B. Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells. Eur. J. Pharmacol. 1996, 316:369-372.
31. Enggaard T.P., Poulsen L., Arendt-Nielsen L., Brosen K., Ossig J., Sindrup S.H. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth. Analg. 2006, 102:146-150.
32. Stamer U.M., Lehnen K., Hothker F., Bayerer B., Wolf S., Hoeft A., Stuber F. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003, 105:231-238.
33. Wang G., Zhang H., He F., Fang X. Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. Eur. J. Clin. Pharmacol. 2006, 62:927-931.
34. Pedersen R.S., Damkier P., Brosen K. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur. J. Clin. Pharmacol. 2006, 62:513-521.
35. Stamer U.M., Musshoff F., Kobilay M., Madea B., Hoeft A., Stuber F. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin. Pharmacol. Ther. 2007, 82:41-47.
36. Garcia-Quetglas E., Azanza J.R., Sadaba B., Munoz M.J., Gil I., Campanero M.A. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype. Pharmacol. Res. 2007, 55:122-130.
37. Kirchheiner J., Keulen J.T., Bauer S., Roots I., Brockmoller J. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J. Clin. Psychopharmacol. 2008, 28:78-83.
38. Stamer U.M., Stuber F., Muders T., Musshoff F. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth. Analg. 2008, 107:926-929.
39. Lalovic B., Kharasch E., Hoffer C., Risler L., Liu-Chen L.Y., Shen D.D. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin. Pharmacol. Ther. 2006, 79:461-479.
40. Heiskanen T.E., Lemberg K.K., Neuvonen M., Kontinen V.K., Neuvonen P.J., Dahl M.L., Kalso E.A. Does co-administration of paroxetine change oxycodone analgesia: an interaction study in chronic pain patients. Scand. J. Pain 2010, 1:24-33.
41. Zwisler S.T., Enggaard T.P., Mikkelsen S., Brosen K., Sindrup S.H. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. Acta Anaesthesiol. Scand. 2010, 54:232-240.
42. Zwisler S.T., Enggaard T.P., Noehr-Jensen L., Pedersen R.S., Mikkelsen S., Nielsen F., Brosen K., Sindrup S.H. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic Clin. Pharmacol. Toxicol. 2009, 104:335-344.
43. Nieminen T.H., Hagelberg N.M., Saari T.I., Pertovaara A., Neuvonen M., Laine K., Neuvonen P.J., Olkkola K.T. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology 2009, 110:1371-1378.
44. Shaiova L., Berger A., Blinderman C.D., Bruera E., Davis M.P., Derby S., Inturrisi C., Kalman J., Mehta D., Pappagallo M., Perlov E. Consensus guideline on parenteral methadone use in pain and palliative care. Palliat. Support Care 2008, 6:165-176.
45. Bruera E., Sweeney C. Methadone use in cancer patients with pain: a review. J. Palliat. Med. 2002, 5:127-138.
46. Ansermot N., Albayrak O., Schlapfer J., Crettol S., Croquette-Krokar M., Bourquin M., Deglon J.J., Faouzi M., Scherbaum N., Eap C.B. Substitution of (R,S)-methadone by (R)-methadone: Impact on QTc interval. Arch. Intern. Med. 2010, 170:529-536.
47. Crettol S., Deglon J.J., Besson J., Croquette-Krokar M., Hammig R., Gothuey I., Monnat M., Eap C.B. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin. Pharmacol. Ther. 2006, 80:668-681.
48. Lotsch J., Skarke C., Wieting J., Oertel B.G., Schmidt H., Brockmoller J., Geisslinger G. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin. Pharmacol. Ther. 2006, 79:72-89.
49. de los Cobos J., Valero S., Haro G., Fidel G., Escuder G., Trujols J., Valderrama J.C. Development and psychometric properties of the Verona Service Satisfaction Scale for methadone-treated opioid-dependent patients (VSSS-MT). Drug Alcohol Depend. 2002, 68:209-214.
50. Coller J.K., Joergensen C., Foster D.J., James H., Gillis D., Christrup L., Somogyi A.A. Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone. Int. J. Clin. Pharmacol. Ther. 2007, 45:410-417.
51. Kirchheiner J., Nickchen K., Bauer M., Wong M.L., Licinio J., Roots I., Brockmoller J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 2004, 9:442-473.
52. Steimer W., Zopf K., von Amelunxen S., Pfeiffer H., Bachofer J., Popp J., Messner B., Kissling W., Leucht S. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin. Chem. 2005, 51:376-385.
53. Kaiser R., Sezer O., Papies A., Bauer S., Schelenz C., Tremblay P.B., Possinger K., Roots I., Brockmoller J. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J. Clin. Oncol. 2002, 20:2805-2811.
54. Candiotti K.A., Birnbach D.J., Lubarsky D.A., Nhuch F., Kamat A., Koch W.H., Nikoloff M., Wu L., Andrews D. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis?. Anesthesiology 2005, 102:543-549.
55. Brauch H., Murdter T.E., Eichelbaum M., Schwab M. Pharmacogenomics of tamoxifen therapy. Clin. Chem. 2009, 55:1770-1782.
56. Clarke R., Leonessa F., Welch J.N., Skaar T.C. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol. Rev. 2001, 53:25-71.
57. Jordan V.C., Collins M.M., Rowsby L., Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol. 1977, 75:305-316.
58. Allen K.E., Clark E.R., Jordan V.C. Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships. Br. J. Pharmacol. 1980, 71:83-91.
59. Borges S., Desta Z., Li L., Skaar T.C., Ward B.A., Nguyen A., Jin Y., Storniolo A.M., Nikoloff D.M., Wu L., Hillman G., Hayes D.F., Stearns V., Flockhart D.A. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 2006, 80:61-74.
60. Stearns V., Johnson M.D., Rae J.M., Morocho A., Novielli A., Bhargava P., Hayes D.F., Desta Z., Flockhart D.A. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 2003, 95:1758-1764.
61. Jin Y., Desta Z., Stearns V., Ward B., Ho H., Lee K.H., Skaar T., Storniolo A.M., Li L., Araba A., Blanchard R., Nguyen A., Ullmer L., Hayden J., Lemler S., Weinshilboum R.M., Rae J.M., Hayes D.F., Flockhart D.A. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. 2005, 97:30-39.
62. Lim H.S., Ju Lee H., Seok Lee K., Sook Lee E., Jang I.J., Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J. Clin. Oncol. 2007, 25:3837-3845.
63. Spina E., Santoro V., D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin. Ther. 2008, 30:1206-1227.
64. Brauch H., Jordan V.C. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?. Eur. J. Cancer. 2009, 45:2274-2283.
65. Kiyotani K., Mushiroda T., Imamura C.K., Hosono N., Tsunoda T., Kubo M., Tanigawara Y., Flockhart D.A., Desta Z., Skaar T.C., Aki F., Hirata K., Takatsuka Y., Okazaki M., Ohsumi S., Yamakawa T., Sasa M., Nakamura Y., Zembutsu H. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J. Clin. Oncol. 2010, 28:1287-1293.
66. Goetz M.P., Knox S.K., Suman V.J., Rae J.M., Safgren S.L., Ames M.M., Visscher D.W., Reynolds C., Couch F.J., Lingle W.L., Weinshilboum R.M., Fritcher E.G., Nibbe A.M., Desta Z., Nguyen A., Flockhart D.A., Perez E.A., Ingle J.N. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 2007, 101:113-121.
67. Schroth W., Antoniadou L., Fritz P., Schwab M., Muerdter T., Zanger U.M., Simon W., Eichelbaum M., Brauch H. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 2007, 25:5187-5193.
68. Xu Y., Sun Y., Yao L., Shi L., Wu Y., Ouyang T., Li J., Wang T., Fan Z., Fan T., Lin B., He L., Li P., Xie Y. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann. Oncol. 2008, 19:1423-1429.
69. Kiyotani K., Mushiroda T., Sasa M., Bando Y., Sumitomo I., Hosono N., Kubo M., Nakamura Y., Zembutsu H. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 2008, 99:995-999.
70. Nowell S.A., Ahn J., Rae J.M., Scheys J.O., Trovato A., Sweeney C., MacLeod S.L., Kadlubar F.F., Ambrosone C.B. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res. Treat. 2005, 91:249-258.
71. Wegman P., Elingarami S., Carstensen J., Stal O., Nordenskjold B., Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res. 2007, 9:R7.
72. Wegman P., Vainikka L., Stal O., Nordenskjold B., Skoog L., Rutqvist L.E., Wingren S. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 2005, 7:R284-290.
73. Goetz M.P., Rae J.M., Suman V.J., Safgren S.L., Ames M.M., Visscher D.W., Reynolds C., Couch F.J., Lingle W.L., Flockhart D.A., Desta Z., Perez E.A., Ingle J.N. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 2005, 23:9312-9318.
74. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., Hoctin-Boes G., Houghton J., Locker G.Y., Tobias J.S. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62.
75. Park H.J., Shinn H.K., Ryu S.H., Lee H.S., Park C.S., Kang J.H. Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clin. Pharmacol. Ther. 2007, 81:539-546.
76. Zwisler S.T., Enggaard T.P., Noehr-Jensen L., Mikkelsen S., Verstuyft C., Becquemont L., Sindrup S.H., Brosen K. The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundam. Clin. Pharmacol. 2009.
77. Campa D., Gioia A., Tomei A., Poli P., Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin. Pharmacol. Ther. 2008, 83:559-566.
78. Lotsch J., von Hentig N., Freynhagen R., Griessinger N., Zimmermann M., Doehring A., Rohrbacher M., Sittl R., Geisslinger G. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet. Genomics 2009, 19:429-436.
79. Levran O., O'Hara K., Peles E., Li D., Barral S., Ray B., Borg L., Ott J., Adelson M., Kreek M.J. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum. Mol. Genet. 2008, 17:2219-2227.
80. Coller J.K., Barratt D.T., Dahlen K., Loennechen M.H., Somogyi A.A. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin. Pharmacol. Ther. 2006, 80:682-690.
81. Crettol S., Deglon J.J., Besson J., Croquette-Krokar M., Hammig R., Gothuey I., Monnat M., Eap C.B. No influence of ABCB1 haplotypes on methadone dosage requirement. Clin. Pharmacol. Ther. 2008, 83:668-669. author reply 669-670.
82. Klepstad P., Rakvag T.T., Kaasa S., Holthe M., Dale O., Borchgrevink P.C., Baar C., Vikan T., Krokan H.E., Skorpen F. The 118 A>G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol. Scand. 2004, 48:1232-1239.
83. Walter C., Lotsch J. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 2009, 146:270-275.
84. Janicki P.K., Schuler G., Francis D., Bohr A., Gordin V., Jarzembowski T., Ruiz-Velasco V., Mets B. A genetic association study of the functional A118G polymorphism of the human mu-opioid receptor gene in patients with acute and chronic pain. Anesth. Analg. 2006, 103:1011-1017.
85. Coulbault L., Beaussier M., Verstuyft C., Weickmans H., Dubert L., Tregouet D., Descot C., Parc Y., Lienhart A., Jaillon P., Becquemont L. Environmental and genetic factors associated with morphine response in the postoperative period. Clin. Pharmacol. Ther. 2006, 79:316-324.
86. Huehne K., Leis S., Muenster T., Wehrfritz A., Winter S., Maihofner C., Foertsch T., Croner R., Reis A., Winterpacht A., Rautenstrauss B. High post surgical opioid requirements in Crohn's disease are not due to a general change in pain sensitivity. Eur. J. Pain 2009, 13:1036-1042.
87. Landau R. One size does not fit all: genetic variability of mu-opioid receptor and postoperative morphine consumption. Anesthesiology 2006, 105:235-237.
88. Lotsch J. Basic genetic statistics are necessary in studies of functional associations in anesthesiology. Anesthesiology 2007, 107:168-169. (author reply 169).
89. Chanock S.J., Manolio T., Boehnke M., Boerwinkle E., Hunter D.J., Thomas G., Hirschhorn J.N., Abecasis G., Altshuler D., Bailey-Wilson J.E., Brooks L.D., Cardon L.R., Daly M., Donnelly P., Fraumeni J.F., Freimer N.B., Gerhard D.S., Gunter C., Guttmacher A.E., Guyer M.S., Harris E.L., Hoh J., Hoover R., Kong C.A., Merikangas K.R., Morton C.C., Palmer L.J., Phimister E.G., Rice J.P., Roberts J., Rotimi C., Tucker M.A., Vogan K.J., Wacholder S., Wijsman E.M., Winn D.M., Collins F.S. Replicating genotype-phenotype associations. Nature 2007, 447:655-660.
90. Zubieta J.K., Heitzeg M.M., Smith Y.R., Bueller J.A., Xu K., Xu Y., Koeppe R.A., Stohler C.S., Goldman D. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 2003, 299:1240-1243.
91. Reyes-Gibby C.C., Shete S., Rakvag T., Bhat S.V., Skorpen F., Bruera E., Kaasa S., Klepstad P. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 2007, 130:25-30.
92. Kim H., Neubert J.K., San Miguel A., Xu K., Krishnaraju R.K., Iadarola M.J., Goldman D., Dionne R.A. Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain 2004, 109:488-496.
93. Kim H., Lee H., Rowan J., Brahim J., Dionne R.A. Genetic polymorphisms in monoamine neurotransmitter systems show only weak association with acute post-surgical pain in humans. Mol. Pain 2006, 2:24.
94. Birklein F., Depmeier C., Rolke R., Hansen C., Rautenstrauss B., Prawitt D., Magerl W. A family-based investigation of cold pain tolerance. Pain 2008, 138:111-118.
95. Rakvag T.T., Klepstad P., Baar C., Kvam T.M., Dale O., Kaasa S., Krokan H.E., Skorpen F. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005, 116:73-78.
96. Rakvag T.T., Ross J.R., Sato H., Skorpen F., Kaasa S., Klepstad P. Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol. Pain 2008, 4:64.
97. Ross J.R., Riley J., Taegetmeyer A.B., Sato H., Gretton S., du Bois R.M., Welsh K.I. Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer 2008, 112:1390-1403.
98. Shah R.R. Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2005, 360:1617-1638.
99. Kim H., Clark D., Dionne R.A. Genetic contributions to clinical pain and analgesia: avoiding pitfalls in genetic research. J. Pain 2009, 10:663-693.
100. Tegeder I. Current evidence for a modulation of low back pain by human genetic variants. J. Cell. Mol. Med. 2009, 13:1605-1619.
101. Somogyi A.A., Barratt D.T., Coller J.K. Pharmacogenetics of opioids. Clin. Pharmacol. Ther. 2007, 81:429-444.
102. Slade G.D., Diatchenko L., Bhalang K., Sigurdsson A., Fillingim R.B., Belfer I., Max M.B., Goldman D., Maixner W. Influence of psychological factors on risk of temporomandibular disorders. J. Dent. Res. 2007, 86:1120-1125.
103. George S.Z., Wallace M.R., Wright T.W., Moser M.W., Greenfield W.H., Sack B.K., Herbstman D.M., Fillingim R.B. Evidence for a biopsychosocial influence on shoulder pain: pain catastrophizing and catechol-O-methyltransferase (COMT) diplotype predict clinical pain ratings. Pain 2008, 136:53-61.
104. Hapgood R. The potential and limitations of personalized medicine in the doctor-patient relationship. Pharmacogenomics 2003, 4:685-687.
105. Schroth W., Goetz M.P., Hamann U., Fasching P.A., Schmidt M., Winter S., Fritz P., Simon W., Suman V.J., Ames M.M., Safgren S.L., Kuffel M.J., Ulmer H.U., Bolander J., Strick R., Beckmann M.W., Koelbl H., Weinshilboum R.M., Ingle J.N., Eichelbaum M., Schwab M., Brauch H. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009, 302:1429-1436.
106. Bijl M.J., van Schaik R.H., Lammers L.A., Hofman A., Vulto A.G., van Gelder T., Stricker B.H., Visser L.E. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res. Treat. 2009, 118:125-130.
107. Newman W.G., Hadfield K.D., Latif A., Roberts S.A., Shenton A., McHague C., Lalloo F., Howell S., Evans D.G. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin. Cancer Res. 2008, 14:5913-5918.